|
2025 Journal Article Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9 |
|
2025 Journal Article Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)Conduit, Ciara, Inderjeeth, Andrisha-Jade, Allen, Raymond, Martin, Andrew J., Parulekar, Wendy, Mulroe, Eibhlin, McJannett, Margaret, Zielinski, Robert R., Thomson, Alastair, Tan, Thean Hsiang, Sandhu, Shahneen K., Reaume, M. Neil, Pook, David W., North, Scott A., Marx, Gavin M., Joshua, Anthony, Horvath, Lisa, McDermott, Ray, Chowdhury, Simon, Chi, Kim N., Zhang, Alison Y., Stockler, Martin R., Davis, Ian D., Sweeney, Christopher J. and on behalf of ANZUP Cancer Trials Group (2025). Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304). Future Oncology, ahead-of-print (ahead-of-print), 1-10. doi: 10.1080/14796694.2024.2440277 |
|
2025 Journal Article Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trialRobledo, Kristy P, Rieger, Ingrid, Finlayson, Sarah, Tarnow-Mordi, William and Martin, Andrew J (2025). Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trial. Archives of Disease in Childhood: Fetal and Neonatal Edition, fetalneonatal-2024. doi: 10.1136/archdischild-2024-327762 |
|
2024 Journal Article Understanding regional aerosol deposition in pediatric airways during oral breathing: Insights from computational modelingPillay, Kineshta, Finlay, Warren H. and Martin, Andrew R. (2024). Understanding regional aerosol deposition in pediatric airways during oral breathing: Insights from computational modeling. Journal of Aerosol Science, 182 106438. doi: 10.1016/j.jaerosci.2024.106438 |
|
2024 Journal Article Can we use viral receptor mapping and particle deposition models to predict the clinical severity of novel airborne pathogens?Pillay, Kineshta, Marr, Linsey C., Henriques, Andre, Martin, Andrew R., Prussin, Aaron J., Aleixo, Luis, Andreini, Marco, Mounet, Nicolas, Finlay, Warren H. and Tang, Julian W. (2024). Can we use viral receptor mapping and particle deposition models to predict the clinical severity of novel airborne pathogens?. Clinical Microbiology and Infection, 31 (4), 503-505. doi: 10.1016/j.cmi.2024.11.005 |
|
2024 Journal Article INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric CancerPavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin, Martin, Andrew, Jaworski, Anthony, Tebbutt, Niall, Bang, Yung-Jue, Alcindor, Thierry, O'Callaghan, Chris, Strickland, Andrew, Rha, Sun Young, Lee, Keun-Wook, Kim, Jin-Soo, Bai, Li-Yuan, Hara, Hiroki, Oh, Do-Youn, Yip, Sonia, Zalcberg, John, Price, Tim, Simes, John and Goldstein, David (2024). INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer. Journal of Clinical Oncology, 43 (4), 453-463. doi: 10.1200/jco.24.00055 |
|
2024 Conference Publication EV430/#358 Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysisObermair, Andreas, West, Zoe, Baxter, Eva, Condous, George, Hacker, Neville, Lord, Sally, Mccarthy, Sandie, Janda, Monika, Tuffaha, Haitham, Hayes, Sandi, Disipio, Tracey, Mellon, Anne, Gebski, Val, Mcnally, Orla and Martin, Andrew (2024). EV430/#358 Benefit-harm trade-off for groin node dissection versus groin ultrasound monitoring to reduce the risk of surgery-related morbidity in vulvar cancer – a decision-tree analysis. IGCS 2024 Annual Meeting, Dublin, Ireland, 16-18 October 2024. London, United Kingdom: BMJ Group. doi: 10.1136/ijgc-2024-igcs.551 |
|
2024 Journal Article Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate CancerSoon, Yu Yang, Marschner, Ian C., Schou, Manjula, Hofman, Michael S., Emmett, Louise, Davis, Ian D., Stockler, Martin R. and Martin, Andrew J. (2024). Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 7 (9) e2433863, e2433863. doi: 10.1001/jamanetworkopen.2024.33863 |
|
2024 Journal Article Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritanceSharifi, Nima, Diaz, Robert, Lin, Hui-Ming, Roberts, Evan, Horvath, Lisa G., Martin, Andrew, Stockler, Martin R., Yip, Sonia, Subhash, Vinod V., Portman, Neil, Davis, Ian D. and Sweeney, Christopher J. (2024). Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance. Journal of Clinical Investigation, 134 (18) e183583, 1-9. doi: 10.1172/jci183583 |
|
2024 Journal Article Challenges of estimating treatment effects after a positive interim analysisSoon, Yu Yang, Marschner, Ian C., Schou, Manjula, Sweeney, Christopher J., Davis, Ian D., Stockler, Martin R. and Martin, Andrew J. (2024). Challenges of estimating treatment effects after a positive interim analysis. European Journal of Cancer, 209 114230, 114230. doi: 10.1016/j.ejca.2024.114230 |
|
2024 Conference Publication Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)Hamid, A.A., Thomas, H., Martin, A., Soon, Y.Y., Horvath, L.G., Zielinski, R., Thomson, A., Tan, H., Sandhu, S.K., Reaume, M.N., Pook, D.W., Parnis, F., McDermott, R.S., Lawrence, N., Frydenberg, M., Chi, K.N., Stockler, M.R., Davis, I.D. and Sweeney, C. (2024). Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.1699 |
|
2024 Conference Publication Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)Horvath, L.G., Lin, H-M., Davis, I.D., Martin, A., Scheinberg, T., Meikle, P., Joshua, A., Mcjannett, M., Subhash, V., Yip, S., North, S., McDermott, R.S., Chi, K.N., Stockler, M.R. and Sweeney, C. (2024). Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.1688 |
|
2024 Journal Article Correction to: Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals (Supportive Care in Cancer, (2022), 30, 9, (7763-7772), 10.1007/s00520-022-07167-3)Nahm, Sharon H., Stockler, Martin R., Martin, Andrew J., Grimison, Peter, Fox, Peter, Zielinski, Rob, Hawson, Geoffrey AT., Tattersall, Martin HN. and Kiely, Belinda E. (2024). Correction to: Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals (Supportive Care in Cancer, (2022), 30, 9, (7763-7772), 10.1007/s00520-022-07167-3). Supportive Care in Cancer, 32 (6) 386. doi: 10.1007/s00520-024-08597-x |
|
2024 Conference Publication Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [<sup>177</sup>Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Kwan, Edmond Michael, Hofman, Michael S., Ng, Sarah W. S., Emmett, Louise, Sandhu, Shahneen, Buteau, James Patrick, Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze Ting, Scott, Andrew Mark, Martin, Andrew James, Stockler, Martin R., Donnellan, Gráinne, Annala, Matti, Tolmeijer, Sofie H., Azad, Arun, Davis, Ian D., Wyatt, Alexander William and TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2024). Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May-4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.5055 |
|
2024 Journal Article [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Gedye, Craig, Rutherford, Natalie K., Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P., Voskoboynik, Mark, Redfern, Andrew D., Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Davis, Ian D. (2024). [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology, 25 (5), 563-571. doi: 10.1016/s1470-2045(24)00135-9 |
|
2024 Journal Article Validation of prognostic and predictive models for therapeutic response in patients treated with [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a post hoc analysis from a randomised, open-label, phase 2 trialGafita, Andrei, Martin, Andrew J., Emmett, Louise, Eiber, Matthias, Iravani, Amir, Fendler, Wolfgang P., Buteau, James, Sandhu, Shahneen, Azad, Arun A, Herrmann, Ken, Stockler, Martin R., Davis, Ian D. and Hofman, Michael S. (2024). Validation of prognostic and predictive models for therapeutic response in patients treated with [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a post hoc analysis from a randomised, open-label, phase 2 trial. European Urology Oncology, 8 (1), 21-28. doi: 10.1016/j.euo.2024.03.009 |
|
2024 Journal Article Colorectal cancer survivors' experiences and views of shared and telehealth models of survivorship care: a qualitative studyGore, Claire, Lisy, Karolina, O’Callaghan, Clare, Wood, Colin, Emery, Jon, Martin, Andrew, De Abreu Lourenco, Richard, Schofield, Penelope and Jefford, Michael (2024). Colorectal cancer survivors' experiences and views of shared and telehealth models of survivorship care: a qualitative study. Psycho-Oncology, 33 (1) e6265. doi: 10.1002/pon.6265 |
|
2024 Journal Article Characterization of Wearable Respiratory Sensors for Breathing Parameter MeasurementsSabz, Mozhgan, MacLean, Joanna, Martin, Andrew R. and Rouhani, Hossein (2024). Characterization of Wearable Respiratory Sensors for Breathing Parameter Measurements. IEEE Sensors Journal, 24 (20), 32283-32290. doi: 10.1109/jsen.2024.3448539 |
|
2024 Journal Article Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation frameworkCho, Doah, Lord, Sarah J., Ward, Robyn, IJzerman, Maarten, Mitchell, Andrew, Thomas, David M., Cheyne, Saskia, Martin, Andrew, Morton, Rachael L., Simes, John and Lee, Chee Khoon (2024). Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework. Therapeutic Advances in Medical Oncology, 16, 1-20. doi: 10.1177/17588359241273062 |
|
2024 Journal Article Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialHofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R., Williams, Scott G. ... Yip, Sonia (2024). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25 (1), 99-107. doi: 10.1016/s1470-2045(23)00529-6 |
